尿激酶受体衍生肽UPARANT可恢复糖尿病大鼠模型的功能异常视网膜电图及血视网膜屏障渗漏
研究在链脲佐菌素诱导的糖尿病大鼠模型中评估全身给予UPARANT的疗效。糖尿病发病后第4至5周,UPARANT 8 mg/kg每日5天可恢复功能异常视网膜电图,效果持续约2周,并伴血视网膜屏障完整性恢复及炎症和血管生成反应抑制。作者认为靶向尿激酶型纤溶酶原激活物及其受体系统是治疗早期糖尿病视网膜病变的潜在方法。
要点
- UPARANT给药后可在血浆、眼和视网膜中检出,24小时后仍可检测到。
- 糖尿病发病后第4至5周,UPARANT 8 mg/kg每日5天可恢复功能异常视网膜电图,效果持续约2周。
- 8 mg/kg 3天方案或半剂量5天方案无效;视网膜电图恢复伴血视网膜屏障完整性恢复及炎症和血管生成反应抑制。
核心结论
- 数据提示,全身给予UPARANT靶向尿激酶型纤溶酶原激活物及其受体系统是治疗早期糖尿病视网膜病变的潜在方法,为延缓人类疾病进展提供潜在替代途径。
研究设计与样本
- 在健康大鼠中,用质谱法评估UPARANT在血浆、眼和视网膜中的浓度。
- 在链脲佐菌素诱导的糖尿病大鼠模型中,用视网膜电图评估糖尿病视网膜病变的出现,并给予不同剂量和每日方案的UPARANT。
- 用视网膜电图记录、伊文思蓝灌注和实时PCR评估UPARANT疗效,并测定其安全性。
主要发现
- UPARANT给药后很快在血浆、眼和视网膜中出现,24小时后仍可检测到。
- 糖尿病发病后第4至第5周,UPARANT 8 mg/kg每日5天可恢复功能异常视网膜电图,恢复持续约2周。
- 8 mg/kg 3天治疗或半剂量5天治疗无效。
- 视网膜电图恢复伴随血视网膜屏障完整性恢复及炎症和血管生成反应抑制。
- UPARANT显示出安全性特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The activation of the urokinase-type plasminogen activator and its receptor system is associated with retinal diseases. Among peptide inhibitors of this system, UPARANT acts by preventing the onset of pathologic signs of neovascular ocular diseases. We investigated whether systemic UPARANT may act in a therapeutic regimen by suppressing the retinal damage that characterizes diabetic retinopathy using a rat model of streptozotocin-induced diabetes. METHODS: In healthy rats, plasma, eye, and retina concentrations of UPARANT were evaluated by mass spectrometry. In rat models of streptozotocin-induced diabetes, the appearance of diabetic retinopathy was assessed by electroretinogram (ERG). UPARANT was then administered at different dosages and daily regimens. ERG recording, Evans blue perfusion, and real-time PCR were used to evaluate UPARANT efficacy. UPARANT safety was also determined. RESULTS: UPARANT was found in plasma, eye, and retina soon after its administration and remained detectable after 24 hours. Between the 4th and the 5th week after diabetes onset, UPARANT at 8 mg/kg (daily for 5 days) was effective in recovering dysfunctional ERG. Three-day treatments at 8 mg/kg or a half dose for 5 days were ineffective. ERG recovery lasted approximately 2 weeks. ERG recovery was accompanied by restored blood-retinal barrier integrity and inhibition of inflammatory and angiogenic responses. UPARANT showed a safety profile. CONCLUSIONS: These data suggest that targeting the urokinase-type plasminogen activator and its receptor system by systemic UPARANT is a potential therapeutic approach for the treatment of early diabetic retinopathy, thus providing a potential alternative approach to delay disease progression in humans.
引用
- Cammalleri M, Locri F, Marsili S, et al. The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier Leakage in a Rat Model of Diabetes. Invest Ophthalmol Vis Sci. 2017. PMID: 28632880. doi:10.1167/iovs.17-21593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。